drugset
drugset / Trial / NCT05422092

Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

NCT05422092 ↗

Unknown 80 enrolled First Affiliated Hospital Xi'an Jiaotong University
RandomizedParallel-groupOpen-labelDiagnostic

Summary

Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease (NAFLD).This prospective, randomized controlled intervention study was designed to reveal the potential clinical application and underlying mechanisms of canagliflozin in the treatment of type 2 diabetes combined with nonalcoholic fatty liver disease.

Timeline

Start
2022-09-20
Primary completion
2023-01
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg —
Comparator Pioglitazone Small molecule 45 mg —

Indications

type 2 diabetes mellitus